Primary Care Clinics in Yucca Valley, CA Accepting Medicare
26 Primary Care Clinics found. Showing 21 - 26
 Eliott Romero, Md Corp Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 57340 29 Palms Hwy, Yucca Valley, CA 92284 Phone: 760-365-2308 Fax: 760-365-7538 |
Morongo Basin Community Health Center Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Medicare Enrolled Practice Location: 58375 29 Palms Hwy, Yucca Valley, CA 92284 Phone: 760-365-9305 Fax: 866-732-0113 |
Rui A Da Silva, M.d., Inc. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 58471 29 Palms Hwy, Suite 203, Yucca Valley, CA 92284 Phone: 760-365-7651 Fax: 760-365-6050 |
Yucca Family Medical Care, Inc. Clinic/Center - Primary Care Medicare: Medicare Enrolled Practice Location: 57675 29 Palms Hwy, Suite 111, Yucca Valley, CA 92284 Phone: 760-365-8500 Fax: 760-365-8599 |
Morongo Medical Group Inc Internal Medicine Medicare: Medicare Enrolled Practice Location: 57725 29 Palms Hwy, Ste 401, Yucca Valley, CA 92284 Phone: 760-228-1929 Fax: 760-228-9633 |
Morongo Basin Community Health Center-wellness Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Not Enrolled in Medicare Practice Location: 57019 Yucca Trl Ste D, Yucca Valley, CA 92284 Phone: 760-365-9305 |
News Archive
Oncolytics Biotech receives patent for modified reovirus variant
Oncolytics Biotech Inc. today announced that it has been granted U.S. Patent, 7,803,385 entitled Reoviruses Having Modified Sequences. The patent claims cover methods for making and using modified reoviruses, and pharmaceutical compositions that include modified reoviruses.
Recommendation that physicians be a little more cautious in deciding against tPA treatment
Although use of the clot-dissolving drug tissue plasminogen activator (tPA) has revolutionized the treatment of acute stroke patients, many of those who could receive the drug do not because their initial symptoms appear mild or improve soon after they arrive at the hospital.
Sigma Life Science signs license agreement with Horizon Discovery for CompoZr ZFN technology
Sigma-Aldrich Corporation today announced that Sigma Life Science, its innovative biological products and services business, has entered a non-exclusive license agreement with Horizon Discovery for use of Sigma's CompoZr Zinc Finger Nuclease technology.
Enrollment complete in Boehringer Ingelheim's nintedanib phase III studies for IPF
Boehringer Ingelheim Pharmaceuticals, Inc. announced that clinical trial enrollment has completed for two phase III studies evaluating the safety and efficacy of nintedanib (BIBF 1120), an investigational compound, in patients with idiopathic pulmonary fibrosis (IPF), being studied at a twice-daily oral dose.
› Verified 9 days ago
- 1
- 2(current)